News | January 05, 2022
Bharat Biotech's intranasal vaccine Phase 3 trials gets approval
It has also been granted permission to conduct trials for booster dose
It has also been granted permission to conduct trials for booster dose
_256_384.jpg)
Primary endpoints and secondary endpoints for which data are available were met in trial dominated by Covid-19 variants
VIPER AI solutions support care teams by automating the identification of potentially eligible patients at the time of diagnosis and easily matching them to relevant trials
The company has already received the emergency use authorization (EUA) from the Drug Controller General of India (DCGI) for ZyCoV-D to be administered in three doses on August 20
Industry leaders to increase patient access to clinical research and scale remote enrollment of participants for trial sponsors to promote increased health equity
Ampion is directly administered by inhalation and it allows the drug to directly target and attenuate inflammation in the lungs
The Lancet study said that Sputnik Light showed 78.6 to 83.7 per cent efficacy against Covid-19, significantly higher than most two-shot vaccines
This clinical study demonstrated that the 14-day regimen of ImmunoSEB and ProbioSEB CSC3 resolved post-Covid-19 fatigue symptoms and improved patients' functional status and quality of life
First participants enrolled in Phase 1 clinical trial of combination NanoFlu/NVX-CoV2373 vaccine with Matrix-M adjuvant. The Phase 1/2 study will also evaluate immunogenicity and safety
The trial will be conducted across 10 sites in India
Subscribe To Our Newsletter & Stay Updated
